Join us today at the American Society of Hematology’s annual meeting where Senior Scientist, Computational Biology, Bioinformatics, W. Frank Lenoir, PhD, is presenting data from our p300 KAT inhibitor program for #multiplemyeloma
Kronos Bio
生物技术研究
San Mateo，California 9,636 位关注者
We’re focused on creating a world where no life is cut short by cancer or other serious diseases.
关于我们
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma. Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
- 网站
-
https://www.kronosbio.com
Kronos Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Mateo，California
- 类型
- 上市公司
- 创立
- 2017
地点
Kronos Bio员工
动态
-
Join Vice President of Discovery Biology, Peter Rahl, Ph.D., for an oral presentation at #ACRConvergence2024 highlighting preclinical data from our p300 KAT inhibitor program for #autoimmune indications. Learn more here: https://bit.ly/3AIE08g ?
-
-
Join us on December 9th at the American Society of Hematology’s annual meeting where we’ll be presenting preclinical data from our p300 KAT inhibitor program for #multiplemyeloma. Learn more here: https://bit.ly/4hxqLb3 ?
-
-
At Kronos Bio, we believe it’s important to find ways to give back to our local communities. Our team was fortunate to volunteer with Cradles to Crayons, Drumlin Farm, and Samaritan House of San Mateo County?throughout October to help in the fight against clothing insecurity, unsustainable farming, and poverty. A core value for us is strengthening the bonds with those around us and creating positive change in and outside of the lab, so join us in making an impact and uplifting those around you!?https://lnkd.in/gQfVZa2w
-
-
Check out today’s press release and preclinical poster presentation highlighting the importance of p300 KAT inhibition in HPV-driven tumors at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on October 24th at 9:00 AM CEST. Learn More: https://bit.ly/3BUGaSp
-
Today, we’re celebrating Indigenous People’s Day as a way to raise awareness of Indigenous voices and recognize the invaluable contributions these communities continue to make in creating a more inclusive tomorrow. #IndigenousPeoplesDay
-
-
We’re presenting preclinical data from our p300 KAT inhibitor program for human papillomavirus (HPV)-driven tumors at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on October 24th at 9:00 am CEST. Join us in learning how our program may provide innovative targeted therapies against HPV-driven cancers. Learn more here: https://bit.ly/4dHHx4f #ENASymp24?
-
-
Happy Hispanic Heritage Month! Join Kronos Bio in honoring the importance of the rich history and diversity that Hispanic?communities bring to help shape the fields of science and technology and we will continue to celebrate their achievements. #HispanicHeritageMonth
-
-
Today we announced the selection of KB-7898, a p300 KAT inhibitor, our first development candidate for #autoimmunediseases, for the potential treatment of #Sj?grensdisease, a chronic #autoimmunedisease marked by the production of autoantibodies, ongoing inflammation and lymphocytic infiltration of the exocrine glands which may lead to uncomfortable dryness symptoms, known as sicca. Preclinical data will be presented at #ACRConvergence2024. Learn more: https://bit.ly/4eB3O54
-
We’re so grateful to have the opportunity to listen firsthand to the insightful sessions at OCRA’s Virtual International Gynecologic Cancer Conference. Special thanks to the organizers and speakers for their hard work in making it such a meaningful experience and your ongoing support of patients in need. #OCRA #CancerResearch #UniteForHope #ocrahope #ovariancancer?
Ovarian cancer survivors shared advice for managing scanxiety, chemo treatments and more during a compelling online conference session today.